Drug intelligence / Profile preview

IY-NS250

Development stage: Unknown
Lead developer: Il-Yang Pharmaceutical

Overview

IY-NS250 is an investigational drug developed by Il-Yang Pharm. Its mechanism of action is currently unknown, and it does not represent a novel mechanism. The drug has been evaluated in at least one completed Phase 1 clinical trial involving healthy volunteers in Korea, primarily to assess its safety, pharmacokinetics, and pharmacodynamics. No approved indications or adverse events have been reported to date[1][3]. There is no evidence that IY-NS250 has reached approval or advanced beyond early-phase clinical trials.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on IY-NS250.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IY-NS250.

Explore the full profile